US · Healthcare · Biotechnology
EPS came in at -3.03 against a street estimate of -2.58 — a miss of 17.4%.
Analysts rate BioNTech SE a buy (16 buy, 5 hold, 0 sell out of 21) with an average price target of $117.57.
MIXED BioNTech posted weak Q2 revenue (EUR 106M, down 59% YoY) due to collapsed COVID demand and inventory use. Late-stage pipeline advanced with pumitamig Phase II data across tumors; gotistobart showed strong OS signals. FY26 guidance cut 21% midpoint to EUR 1.6–1.9B. Q2 2026 COVID vaccine demand weakness spans all geographies; Germany most acute due to direct market model and inventory drawdown strategy. Analysts pressed on Elfe-D competitive positioning (safety profile vs peers), revenue miss drivers (COVID 80%, lost milestone 20%), and ROSETTA LUNG-02 timing (event-driven; PFS interim before OS). Management emphasized data-driven approach, partner efficiency, and cautious optimism on late-stage readouts despite guidance reset. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 2.33% |
| FMR Inc | 2.27% |
| PRIMECAP Management Company | 1.50% |
| Dodge & Cox | 1.46% |
| Flossbach von Storch AG | 0.89% |
| BlackRock Inc | 0.66% |
| BNP Paribas Arbitrage, SA | 0.66% |
| Temasek Holdings Ltd. | 0.60% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioNTech SE — free to start.
Google PlayApp StoreData updated 2026-09-18.